Why Did FDA Reject BlephEx's Quality Fixes Six Times?

TL;DR

• Company: BlephEx, LLC, Brentwood, TN — maker of the BlephEx Powered Eyelid Cleaning Sponge and the OptiVize ophthalmic electrolysis unit and forceps.
• Date: FDA Warning Letter, MARCS-CMS #725861, issued June 3, 2026; inspection ran October 30–November 19, 2025.
• Classification: Medical device — unapproved device marketing, misbranding, and seven separate Quality System Regulation (21 CFR 820) violations.
• Key citations: 21 U.S.C. §§ 351(f)(1)(B), 352(o), 352(t)(2); 21 CFR 820.198(a), 820.100(a)-(b), 820.30(a) & (i), 820.50(a), 820.184, 820.25(b), 820.22.
• Consequence: FDA rejected six consecutive company responses (December 2025 through May 2026) as inadequate; one complaint-handling failure is an explicit repeat of a violation cited on a Form FDA 483 from a March 2019 inspection.

"The handpiece or 'Type G' charger... emitted smoke or blew up." That line, buried in the middle of FDA's Warning Letter to BlephEx, LLC, MARCS-CMS #725861, issued June 3, 2026, describes a charger failure the company knew about and partially fixed. What FDA's letter documents is everything the company didn't do afterward: no root-cause investigation, no corrective-action record, no report to FDA within the required window. Multiply that gap across complaint handling, design controls, supplier oversight, and internal audits, and the letter reads less like a single bad inspection than like a quality system that had quietly stopped functioning years earlier.

FDA's Center for Devices and Radiological Health inspected BlephEx's Brentwood, Tennessee facility from October 30 through November 19, 2025. The agency's letter to owner and president James M. Rynerson, M.D., covers three products: the BlephEx Powered Eyelid Cleaning Sponge, the OptiVize Ophthalmic Battery-Powered Electrolysis Unit, and the OptiVize Ophthalmic Forceps.

The devices outgrew their own clearance

BlephEx's regulatory story starts in 2017. That July, the firm asked FDA to classify its "Eyelid Cleaning Product" under 21 CFR 878.4820, a Class I category exempt from 510(k) review, describing the device as hygiene-only: not intended to cure, treat, or mitigate any disease. FDA agreed, in a September 2017 letter, that the device fit that exemption — as described.

By the time of the 2025 inspection, the marketing had moved. FDA's letter cites BlephEx's own website and product videos promoting the Sponge for treating blepharitis and dry eye disease, and for use in pre-cataract and pre-LASIK patients — populations FDA calls out as carrying "unique risks that go beyond standard eyelid hygiene" because of already-inflamed, fragile eyelid tissue. A device cleared as a hygiene tool was being marketed as a treatment. FDA's conclusion: because the actual intended use now differs from the cleared generic type, the exemption no longer applies, and the Sponge is adulterated under 21 U.S.C. § 351(f)(1)(B) for lacking a premarket approval or investigational device exemption, and misbranded under 21 U.S.C. § 352(o) for skipping the 510(k) notification that change required.

The OptiVize Electrolysis Unit and Forceps drew the same two-part citation for a different reason: different technology, not just different marketing. FDA found the Electrolysis Unit delivers "a precise harmonic waveform" through an eyelid conduction plate, where the cleared category (21 CFR 886.4250) is built around a galvanic electrical current passed through the lash root. The Forceps use built-in heat and vibration to break up meibomian gland blockages, functions absent from the manual, nonpowered instruments covered by 21 CFR 886.4350. Different mechanism, different mode of action, same regulatory outcome: FDA classified both as adulterated and misbranded for marketing outside their cleared scope without new 510(k) submissions.

A charger that "blew up" and a report that never came

Separately from the device-clearance issue, FDA cited a Reports of Corrections and Removals violation under 21 CFR Part 806. In at least three logged incidents in late 2024 and early 2025, a BlephEx handpiece or its "Type G" charger overheated, smoked, or, in FDA's words, "blew up." The firm's fix arrived in October 2024: it shipped USB-A replacement chargers to a distributor with instructions to discontinue the original Type G assemblies.

Swapping the charger was, on its own, a reasonable response. What FDA says didn't happen next is the problem. Federal regulation requires a firm to report a correction or removal undertaken to reduce a health risk to FDA within 10 working days of initiating it, under 21 CFR 806.10. FDA determined a charger that can smoke or explode presents exactly that kind of risk. As of the inspection's close in November 2025, a full year after the charger swap, no such report existed. Three company responses tried to close the gap with retroactive MDR paperwork; FDA found none of them adequate, and as of the firm's fifth update in May 2026, the report still hadn't been filed.

Seven quality-system failures, one common thread

FDA's largest citation covers the Quality System Regulation at 21 CFR Part 820, and the thread running through all seven findings is the same: procedures existed on paper but were not run.

Complaint handling (21 CFR 820.198(a)). BlephEx's Complaint Log recorded more than 177 complaints about the Sponge as "opened," with no closing dates, no individual complaint files, and no documented decision on whether any of them warranted formal investigation. This is not a first offense. FDA's letter states plainly that the finding "is a repeat violation cited on the Form FDA 483, issued for the previous March 27–28, 2019 inspection." Six years separate the two citations for the same underlying failure.

Corrective and preventive action (21 CFR 820.100(a)-(b)). The firm's VP of Operations told investigators no CAPA had been opened since August 2023, and that he was unaware of any opened before that date. The charger failures behind the smoking-and-exploding complaints never generated a CAPA at all.

Design controls (21 CFR 820.30(a) and (i)). BlephEx had no design control procedures for any of its three devices, and no process for reviewing or validating design changes before rolling them out — a gap that directly explains why the October 2024 charger swap shipped without verification that it fixed the underlying failure.

Supplier controls (21 CFR 820.50(a)). The firm's own supplier-qualification procedure required a quality agreement with its BlephEx Lid Cleanser contract manufacturer. No such agreement existed at the time of inspection.

Device history records (21 CFR 820.184), training (21 CFR 820.25(b)), and quality audits (21 CFR 820.22) round out the list. On training and audits specifically, the same VP of Operations who had overseen the quality system since August 2023 — more than 27 months by the time of the inspection — had received no training on quality system requirements during that period, and the system itself had never been audited internally.

What six response letters and no fix look like

BlephEx did not ignore the warning letter's precursor, the Form FDA 483. The company answered it six times: December 12, 2025; January 30, February 27, March 31, April 30, and May 29, 2026. FDA reviewed every one and rejected every one, using close to identical language across multiple citations: "critical deficiencies remain unaddressed 191 days after the inspection closeout."

That phrase, repeated across the complaint-handling, CAPA, design-control, and training findings, is worth sitting with. It is not FDA saying the company did nothing. New procedures were written: a Complaint Handling Procedure, a CAPA Procedure, a Quality Audit Procedure, a Purchasing and Supplier Management Procedure, all adopted between December 2025 and February 2026. What FDA found missing, letter after letter, was evidence the paperwork changed practice: no sample complaint files under the new process, no completed internal audits under the new procedure, no verification that a supplier agreement signed in April 2026 was actually being followed.

FDA's letter closes with a separate note on timing: a final rule effective February 2, 2026 formally renamed 21 CFR Part 820 the Quality Management System Regulation (QMSR), aligning it with the international ISO 13485 standard. BlephEx's inspection was conducted under the prior Quality System Regulation, but FDA specified that any corrective actions the firm implements going forward must meet the new QMSR requirements — meaning the fixes still owed from this letter are due against a regulation that has already changed since the inspection happened.

What other device makers should take from this

The recurring detail across all seven quality-system findings is not any single missing document. It's the six-year gap between the 2019 complaint-handling citation and its 2025 repeat, and the 27-month gap during which a device maker's own quality lead operated without training on the system he was responsible for. Both point to the same underlying risk: a CAPA or complaint-handling procedure that exists in a binder but isn't run day to day will surface again at the next inspection, on the same citation, however much time has passed.

For compliance teams managing 510(k)-cleared or De Novo-authorized devices, this letter is also a reminder that marketing claims can outgrow a clearance even when the hardware doesn't change. BlephEx's Sponge kept its original design; what moved was the claim about what it treats. Reviewing marketing copy against the specific intended use in a device's clearance letter, not just against the device's general category, is a cheaper check than the one FDA ran here.

FAQ

What did FDA's warning letter to BlephEx cite?

Unapproved device marketing for three products (adulteration under 21 U.S.C. § 351(f)(1)(B) and misbranding under § 352(o)), a Reports of Corrections and Removals violation for an unreported charger-related correction, a Global Unique Device Identification Database (GUDID) submission failure, and seven separate Quality System Regulation violations under 21 CFR Part 820, in Warning Letter MARCS-CMS #725861, issued June 3, 2026.

Why is the BlephEx Powered Eyelid Cleaning Sponge no longer covered by its 2017 exemption?

FDA cleared the device in 2017 as a Class I, 510(k)-exempt hygiene product under 21 CFR 878.4820, based on BlephEx's own description of it as non-treatment. By the 2025 inspection, FDA found the firm marketing the Sponge for treating blepharitis and dry eye disease and for use in pre-cataract and pre-LASIK patients, an intended use FDA says exceeds the original exemption's limitations.

Has BlephEx been cited for these issues before?

Yes, at least in part. FDA's letter states that the complaint-handling violation under 21 CFR 820.198(a) "is a repeat violation cited on the Form FDA 483, issued for the previous March 27–28, 2019 inspection."

Did BlephEx respond to the warning letter's underlying 483?

Yes, six times, between December 12, 2025 and May 29, 2026. FDA reviewed each response and found all six inadequate to resolve the underlying violations as of the letter's June 3, 2026 issue date.

Source: FDA Warning Letter, MARCS-CMS #725861, June 3, 2026. Byline: The Argus Regulatory Analysis Team. Published 2026-07-15.

See what a same-day FDA enforcement brief looks like — sample brief →